Eosinophilic Granulomatosis with Polyangiitis (Churg-Strauss)

1. Executive Overview: Understanding EGPA (Churg-Strauss Syndrome)

Eosinophilic Granulomatosis with Polyangiitis (EGPA), historically known as Churg-Strauss Syndrome (ICD-10: M30.1), is a rare, systemic, small-to-medium vessel necrotizing vasculitis. It is characterized by the triad of asthma, peripheral blood eosinophilia, and extravascular granulomatous inflammation.

As a clinical entity, EGPA is categorized under the umbrella of ANCA-associated vasculitides (AAV), though it is unique due to its profound association with eosinophilic inflammation and allergic hypersensitivity. The condition typically progresses through three distinct clinical phases—prodromal, eosinophilic, and vasculitic—though these may overlap. Early recognition is paramount to preventing irreversible end-organ damage, particularly within the pulmonary, cardiac, and neurological systems.

2. Pathophysiology, Etiology, and Risk Factors

The exact etiology of EGPA remains multifactorial, involving a complex interplay between genetic predisposition, environmental triggers, and immune dysregulation.

Pathophysiological Mechanisms

The hallmark of EGPA is the massive infiltration of eosinophils into tissues, causing direct cytotoxic damage. Eosinophils release granular proteins, such as major basic protein (MBP) and eosinophil peroxidase, which induce cellular necrosis and endothelial injury.

• T-Helper 2 (Th2) Polarization: There is a significant skew toward a Th2 immune response, characterized by the overproduction of cytokines like IL-4, IL-5, and IL-13. IL-5, in particular, is the critical driver of eosinophil maturation, recruitment, and survival.
• ANCA Involvement: Approximately 40–60% of patients are positive for Antineutrophil Cytoplasmic Antibodies (ANCA), typically directed against myeloperoxidase (MPO-ANCA). Interestingly, ANCA-positive patients often exhibit more classic vasculitic features (e.g., glomerulonephritis, mononeuritis multiplex), while ANCA-negative patients often present with more cardiac and pulmonary eosinophilic involvement.

Risk Factors

While no single gene is causative, HLA-DRB1 and HLA-DQB1 variants have been linked to susceptibility. Environmental triggers, including viral infections or exposure to certain medications (e.g., leukotriene receptor antagonists), have been clinically observed to precipitate the onset of symptoms in susceptible individuals.

3. Signs, Symptoms, and Clinical Presentation

EGPA follows a predictable, albeit variable, clinical progression.

Systemic Involvement

• Respiratory: Asthma is present in >95% of cases and is often severe and steroid-dependent.
• Dermatological: Palpable purpura, subcutaneous nodules, and urticaria.
• Neurological: Mononeuritis multiplex (foot drop or wrist drop) is a classic indicator of nerve ischemia.
• Cardiac: Myocarditis, pericarditis, and coronary vasculitis. This is the leading cause of mortality in EGPA.
• Renal: Glomerulonephritis, though generally less severe than in other forms of AAV (e.g., GPA or MPA).

4. Standard Diagnostic Evaluation & Workup

Diagnosis is rarely straightforward and requires a high index of clinical suspicion. The 1990 American College of Rheumatology (ACR) criteria and the 2022 ACR/EULAR classification criteria are the standard benchmarks.

Diagnostic Criteria (ACR/EULAR)

To be classified with EGPA, a patient must meet a specific threshold of points based on clinical features, including:
1. Obstructive airway disease
2. Nasal polyposis
3. Peripheral blood eosinophilia
4. Extravascular eosinophilic-predominant inflammation
5. Neuropathy
6. MPO-ANCA or Anti-PR3 positivity

Essential Investigations

• Complete Blood Count (CBC): To identify absolute eosinophil count (AEC).
• Serology: ANCA testing via indirect immunofluorescence and ELISA (MPO/PR3).
• Imaging: High-Resolution Computed Tomography (HRCT) of the chest to identify migratory opacities, ground-glass attenuation, or bronchial wall thickening.
• Tissue Biopsy: The gold standard for definitive diagnosis. Biopsies of affected skin, lung, or nerve tissue reveal necrotizing vasculitis with eosinophilic infiltration and extravascular granulomas.
• Echocardiogram/Cardiac MRI: Essential for assessing cardiac involvement, particularly in patients with unexplained chest pain or elevated troponins.

5. Therapeutic Interventions

Management is risk-stratified using the Five-Factor Score (FFS), which accounts for age, renal insufficiency, proteinuria, cardiomyopathy, and GI involvement.

Pharmacotherapy

1. Glucocorticoids: The cornerstone of induction therapy. High-dose oral prednisone (1 mg/kg/day) is typically initiated, followed by a slow taper.
2. Immunosuppressants: For severe/organ-threatening disease, cyclophosphamide or rituximab is added to the regimen.
3. Biologics (The New Standard): Mepolizumab (an IL-5 antagonist) has been FDA-approved for the treatment of EGPA. It has demonstrated significant efficacy in reducing asthma exacerbations and facilitating the tapering of oral corticosteroids.
4. Maintenance: Azathioprine or methotrexate may be used to maintain remission.

Multidisciplinary Management

Because EGPA affects multiple systems, a multidisciplinary team is mandatory:
* Pulmonology: For asthma and lung disease management.
* Rheumatology: For immunosuppressive coordination.
* Cardiology/Neurology: For monitoring specific end-organ complications.

6. Frequently Asked Questions (FAQ)

1. Is EGPA (Churg-Strauss) considered a terminal illness?
No. While it is a chronic, serious condition, modern therapeutic interventions like biologics and immunosuppressants allow most patients to achieve long-term remission.

2. What is the difference between EGPA and Asthma?
EGPA almost always presents with asthma, but it is distinct because of the systemic inflammation and eosinophil count. Asthma is limited to the airways, while EGPA affects blood vessels throughout the body.

3. Does MPO-ANCA positivity change the prognosis?
ANCA-positive patients are more likely to develop renal disease and vasculitic neuropathy, whereas ANCA-negative patients are more prone to cardiac complications.

4. Can I live a normal life with EGPA?
With consistent monitoring and adherence to treatment, many patients lead productive, active lives. However, regular follow-ups are necessary to manage potential relapses.

5. What is the role of Mepolizumab?
Mepolizumab blocks the IL-5 cytokine, which prevents eosinophils from maturing and surviving. It is highly effective in reducing the need for long-term steroids.

6. Is EGPA hereditary?
EGPA is not considered a hereditary or genetic disease in the classic sense. While there may be a genetic predisposition, it is not passed down directly from parents to children.

7. How often do I need to see my doctor?
Initially, monthly visits are common. Once in remission, most patients are monitored quarterly or semi-annually, depending on their medication regimen.

8. Are there dietary changes that help?
There is no specific "EGPA diet." However, a balanced diet is recommended to mitigate the side effects of long-term corticosteroid use, such as weight gain and bone density loss.

9. Can stress trigger an EGPA flare?
While stress does not cause the disease, physical or emotional stress can potentially trigger immune responses that lead to exacerbations in some patients.

10. What is the "Five-Factor Score" (FFS)?
The FFS is a clinical tool used by doctors to determine the severity of your EGPA and to decide how aggressively to treat the disease with immunosuppressive medications.

Disclaimer: This guide is for educational purposes only and does not substitute professional medical advice. Always consult with your pulmonologist or rheumatologist regarding your specific clinical symptoms.